[
  {
    "letter_name": "1-stop-chicken-health-shop-689150-07292024",
    "violated_terms": [
      "Marketing of unapproved new animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&C Act)",
      "Products are misbranded under section 502(o) of the FD&C Act",
      "Introducing or delivering unapproved and misbranded new animal drugs for introduction into interstate commerce violates section 301(a) of the FD&C Act",
      "Products are not generally recognized as safe and effective under section 201(v) of the FD&C Act",
      "Products are unsafe within the meaning of section 512(a) of the FD&C Act",
      "Products are adulterated under section 501(a)(5) of the FD&C Act"
    ],
    "recommendations": [
      "Investigate and determine the causes of any violations",
      "Implement corrective actions to prevent recurrence of violations",
      "Notify the FDA in writing within fifteen (15) working days of receipt of the letter about the specific steps taken to address violations",
      "Include an explanation of each step being taken to prevent recurrence of violations",
      "Provide copies of related documentation",
      "If unable to complete corrective action within fifteen (15) working days, state the reason for the delay and the time frame for completion",
      "If believing the product is not in violation, include reasoning and supporting information for FDA's consideration"
    ]
  },
  {
    "letter_name": "1-party-time-609781-09012020",
    "violated_terms": [
      "Section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a)",
      "Section 502 of the FD&C Act, 21 U.S.C. § 352",
      "Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)",
      "FTC Act, 15 U.S.C. 41 et seq."
    ],
    "recommendations": [
      "Cease the sale of unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.",
      "Review websites, product labels, and promotional materials to ensure compliance with the FD&C Act.",
      "Email the FDA within 48 hours detailing specific steps taken to correct the violations.",
      "Cease making claims that the product can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.",
      "Email the FTC within 48 hours describing actions taken to address their concerns."
    ]
  },
  {
    "letter_name": "13-vapor-co-llc-619153-11092021",
    "violated_terms": [
      "Failure to obtain marketing authorization for new tobacco products as required under section 910 of the FD&C Act",
      "Manufacturing and distributing adulterated and misbranded tobacco products under sections 902(6)(A) and 903(a)(6) of the FD&C Act",
      "Failure to provide required reports under section 905(j) of the FD&C Act",
      "Prohibited acts under section 301(k) and 301(p) of the FD&C Act"
    ],
    "recommendations": [
      "Discontinue the sale and distribution of the violative tobacco products",
      "Submit a written response within 15 working days detailing corrective actions taken to address the violations",
      "Provide a plan for maintaining compliance with the FD&C Act",
      "Include reasoning and supporting information if disputing the violations"
    ]
  },
  {
    "letter_name": "1-stop-supply-corp-dba-1-stop-vapor-supply-685573-06122024",
    "violated_terms": [
      "Section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) - Definition of tobacco products",
      "Section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) - FDA jurisdiction over tobacco products",
      "Section 910(a) of the FD&C Act (21 U.S.C. § 387j(a)) - Requirement for premarket authorization for new tobacco products",
      "Section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)) - Adulteration of products without marketing authorization",
      "Section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) - Misbranding of products lacking required information under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j))"
    ],
    "recommendations": [
      "Discontinue the sale and distribution of the identified ENDS and e-liquid products lacking marketing authorization.",
      "Submit a written response to the FDA within 15 working days detailing actions taken to address the violations.",
      "Provide a plan for maintaining compliance with the FD&C Act moving forward.",
      "Ensure all tobacco products sold and related advertising comply with the FD&C Act and FDA regulations."
    ]
  },
  {
    "letter_name": "11-11-11-brands-627690-11162022",
    "violated_terms": [
      "Section 402(a)(2)(C)(i) of the FD&C Act - Adulterated food due to unsafe food additive",
      "Section 301(ll) of the FD&C Act - Prohibited act to introduce food with added drug",
      "Section 301(a) of the FD&C Act - Prohibited act to introduce adulterated food into interstate commerce"
    ],
    "recommendations": [
      "Investigate and determine the causes of the violations",
      "Implement corrective actions to prevent recurrence of violations",
      "Notify FDA in writing within fifteen working days of receipt of the letter about specific steps taken to correct the violations",
      "Include an explanation of each step taken and related documentation in the response",
      "If unable to complete corrective action within fifteen working days, provide reasons for the delay and a timeline for completion"
    ]
  }
]